Education
About Us
Working with TipRanks
Follow Us
Quantum-Si (QSI)
NASDAQ:QSI
Top Page
Quantum-Si
(NASDAQ:QSI)
Rating:41Neutral
Price Target:
$1.00
▼(-13.79% Downside)
Positive Factors
International Market
The company emphasized expansion into the international market with 18 international distribution partners to date, which could provide opportunities for revenue growth.
Partnerships
The company's partnership with Avantor is viewed as a tailwind to sales in the biopharma sector.
Product Development
QSI aims to partner with and place Platinum instruments to innovative partners that can help discover new and the potential 'killer app' for its protein sequencers.
Negative Factors
Financial Performance
The company's recent financial performance has been negatively affected by macroeconomic headwinds.
Market Penetration
It may take significant time before QSI can penetrate the protein sequencing opportunity.
Revenue Shortfall
Management reported markedly lower revenue than the consensus expectation, attributing it partially to NIH funding challenges and a shift towards biopharmaceutical companies with longer sales cycles.
Quantum-Si (QSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$236.92M
Dividend YieldN/A
Average Volume (3M)7.18M
Price to Earnings (P/E)―
Beta (1Y)2.61
Revenue Growth100.47%
EPS Growth-5.71%
CountryUS
Employees149
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding182,557,700
10 Day Avg. Volume7,128,365
30 Day Avg. Volume7,184,169
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue45.97
Enterprise Value/Gross Profit86.46
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$2.50Price Target Upside115.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Quantum-Si Business Overview & Revenue Model
Company DescriptionQuantum-Si (QSI) is a biotechnology company focused on revolutionizing the field of proteomics through the development of next-generation protein sequencing technology. The company's core product is the Platinum™ platform, which aims to simplify and accelerate the analysis of proteins. By providing a more comprehensive understanding of proteins, Quantum-Si seeks to advance the discovery and development of new biomarkers and therapeutics, ultimately enhancing personalized medicine approaches.
How the Company Makes MoneyQuantum-Si generates revenue primarily through the sale and deployment of its Platinum™ platform, which includes hardware, software, and consumables used for protein sequencing. The company also offers related services, such as data analysis and interpretation, which provide additional revenue streams. Quantum-Si's revenue model may include direct sales to research institutions, pharmaceutical companies, and clinical laboratories. Additionally, partnerships or collaborations with academic institutions and industry leaders may contribute to its earnings by expanding its market reach and driving adoption of its technology.
Quantum-Si Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While there were significant advancements in product development and strategic initiatives to counteract capital sales challenges, revenue fell short of expectations due to NIH funding uncertainties. The company's strong cash position and innovation roadmap progress are positives, but the lack of financial guidance and increased operating expenses indicate ongoing challenges.Q2-2025 Updates
Positive Updates
Doubling of Pharma and Biotech Opportunity Funnel
Quantum-Si more than doubled its funnel of opportunities in the pharma and biotech sectors from 30 to over 60 opportunities by the end of Q2 2025.
Launch of Expanded Instrument Acquisition Options
To address capital sales headwinds, Quantum-Si launched new instrument acquisition options that do not require upfront capital purchase, leading to initial customer acquisition using this model.
Progress on Innovation Roadmap
The company is on track to launch the version 4 sequencing kit and version 3 library preparation kit, with significant improvements in sample processing and detection capabilities.
Advancements in Proteus Development Program
Key milestones in the Proteus program include successful demonstrations of new fluorescent dyes and wafer-scale surface chemistry processing, setting a foundation for future commercialization.
AI-Driven Amino Acid Recognizer Design
Quantum-Si achieved a significant milestone by using AI to design an amino acid recognizer, speeding up the development process and enhancing proteome coverage potential.
Strong Cash Position
Quantum-Si ended Q2 2025 with $214.2 million in cash, cash equivalents, and investments, with a runway extending into Q2 2028.
Negative Updates
Revenue Below Expectations
Q2 2025 revenue was $591,000, impacted by a near halt in capital purchases by U.S. academic labs due to NIH funding uncertainties.
Increased Operating Expenses
GAAP total operating expenses for Q2 2025 increased to $30.5 million from $26.8 million in Q2 2024, including a $3.4 million expense related to a stockholder litigation settlement.
Uncertainty in NIH Funding Impact
The ongoing uncertainty in NIH funding continues to impact Quantum-Si's revenue, particularly affecting capital sales in the U.S. academic market.
No Financial Guidance Provided
Due to uncertainties in NIH funding and the financial impact of new acquisition models, Quantum-Si did not provide detailed top-line financial guidance for the remainder of 2025.
Company Guidance
During the Quantum-Si Q2 2025 earnings call, the company provided guidance reflecting both challenges and strategic initiatives. Revenue for the quarter was $591,000, with consumable purchases slightly exceeding expectations despite a near halt in capital purchases by U.S. academic labs due to NIH funding uncertainties. The company more than doubled its funnel of opportunities in pharma and biotech, from approximately 30 at the end of Q1 to over 60 by the end of Q2. Gross profit was reported at $351,000 with a gross margin of 59%. Operating expenses were tightly controlled, with GAAP total operating expenses at $30.5 million, slightly higher than the previous year, while adjusted operating expenses were $23.8 million, showcasing efficient cost management. The company revised its annual estimate for adjusted operating expenses to $98 million or less, maintaining a strong cash position of $214.2 million as of June 30, 2025. Quantum-Si introduced new instrument acquisition models to address capital sales headwinds, aiming to grow its installed base and capture more consumable revenue. The company remains confident in its long-term opportunities in proteomics, with a strong innovation pipeline, including the upcoming launch of its version 4 sequencing kit within the quarter, and the Proteus development program on track for a 2026 launch.Quantum-Si Financial Statement Overview
Summary
Quantum-Si is facing significant financial challenges with consistent losses and negative cash flows. While the company maintains a low debt level, its inability to generate positive returns and cash flows poses risks to its financial health. Strategic improvements are necessary to enhance profitability and cash generation.Income Statement
Quantum-Si shows a challenging financial position with negative net profit margins and declining revenue growth. The gross profit margin is positive, indicating some efficiency in production, but the company struggles with high operating losses as reflected in negative EBIT and EBITDA margins.35
Negative
Balance Sheet
The balance sheet reflects a low debt-to-equity ratio, suggesting conservative leverage. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for long-term sustainability.45
Neutral
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, which are concerning. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with reported losses, but the overall cash flow position is weak.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.41M | 3.06M | 1.08M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.81M | 1.60M | 488.00K | -2.58M | -1.04M | -894.00K |
| EBITDA | -106.38M | -103.98M | -91.80M | -129.86M | -95.87M | -35.80M |
| Net Income | -106.46M | -101.01M | -95.96M | -141.04M | -88.95M | -36.61M |
Balance Sheet | ||||||
| Total Assets | 254.41M | 247.87M | 298.25M | 391.49M | 503.23M | 40.59M |
| Cash, Cash Equivalents and Short-Term Investments | 214.21M | 209.60M | 257.74M | 351.31M | 471.30M | 36.91M |
| Total Debt | 11.14M | 12.95M | 15.30M | 17.45M | 8.08M | 1.75M |
| Total Liabilities | 33.42M | 32.45M | 26.63M | 32.78M | 26.19M | 4.50M |
| Stockholders Equity | 220.98M | 215.42M | 271.62M | 358.71M | 477.03M | 36.09M |
Cash Flow | ||||||
| Free Cash Flow | -96.37M | -92.38M | -99.31M | -101.30M | -72.58M | -33.03M |
| Operating Cash Flow | -92.39M | -87.80M | -94.04M | -90.56M | -66.81M | -32.57M |
| Investing Cash Flow | -29.19M | -32.67M | 143.43M | 137.19M | -450.94M | -461.00K |
| Financing Cash Flow | 84.21M | 35.88M | 149.00K | 1.91M | 516.63M | 37.01M |
Quantum-Si Technical Analysis
Negative
1.16
Price Trends
1.58
Negative
1.51
Negative
1.61
Negative
Market Momentum
-0.13
Negative
36.60
Neutral
81.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.58, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 36.60 is Neutral, neither overbought nor oversold. The STOCH value of 81.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QSI.
Quantum-Si Risk Analysis
Quantum-Si disclosed 67 risk factors in its most recent earnings report. Quantum-Si reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quantum-Si Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $540.45M | ― | -51.84% | ― | -100.00% | -25.75% | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
49 Neutral | $117.19M | ― | -25.25% | ― | 12.13% | -8.23% | |
47 Neutral | $289.66M | ― | -32.38% | ― | ― | 23.24% | |
45 Neutral | $312.61M | ― | 322.49% | ― | -31.30% | 36.26% | |
41 Neutral | $236.92M | ― | -46.87% | ― | 100.47% | -5.71% | |
41 Neutral | $89.17M | ― | -31.55% | ― | ― | 6.27% |
* Healthcare Sector Average
Performance Comparison
QSI
Quantum-Si
1.15
0.18
18.56%
NAUT
Nautilus Biotechnolgy
0.69
-1.89
-73.26%
FHTX
Foghorn Therapeutics
5.01
-2.88
-36.50%
AVIR
Atea Pharmaceuticals
3.47
-0.31
-8.20%
CMPX
Compass Therapeutics
3.49
2.13
156.62%
SEER
Seer
2.03
0.32
18.71%
Quantum-Si Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Quantum-Si Updates Corporate Presentation on Growth
Positive
Aug 8, 2025
On August 8, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning and growth in the proteomics market. The company reported a 33% year-over-year growth in its user base for the first half of 2025 and announced the introduction of multiple instrument acquisition options. With a well-capitalized position and a cash runway into Q2 2028, Quantum-Si is poised to expand its market presence further. The company’s Proteus platform, expected to launch in the second half of 2026, is designed to address a broad range of proteomics analysis methods, potentially enhancing its competitive edge in the industry.
Private Placements and Financing
Quantum-Si Announces $50M Securities Purchase Agreement
Neutral
Jul 7, 2025
On July 3, 2025, Quantum-Si Incorporated announced a securities purchase agreement with an institutional investor for a registered direct offering of 29,940,119 shares of common stock, expected to generate approximately $50 million in gross proceeds. The company plans to use the funds for product development, commercialization, and general corporate purposes, with the offering expected to close on July 8, 2025, subject to customary conditions.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.